1. Regulatory Framework for Clinical Trial Applications in the EU/EEA
The authorization of clinical trials within the European Union is governed by Regulation (EU) No 536/2014 on Clinical Trials (CTR). This regulation establishes a harmonized process for the assessment and supervision of clinical trial applications across EU Member States and EEA countries.
Under the CTR, sponsors are required to submit a single application via the Clinical Trials Information System (CTIS), an EU-wide online platform, to seek approval for conducting clinical trials in one or multiple Member States/EEA countries.
CTR 536/2014 replaces the previous regulatory framework, streamlining procedures and enhancing transparency throughout the clinical trial lifecycle. As of 31 January 2023, all new clinical trial applications must be submitted through CTIS. Furthermore, from 31 January 2025, all ongoing trials initially approved under the former Clinical Trials Directive 2001/20/EC must be transitioned into CTIS and brought into full compliance with the requirements of CTR 536/2014.
Key Regulatory Authorities:
- European Medicines Agency (EMA) – Oversees the implementation of the Clinical Trials Regulation and manages the CTIS platform
- EU/EEA member states – The appointed Reporting Member State (RMS) is responsible for initial assessment of the clinical trial application as well as the draft assessment report. Concerned Member States (CMS) review the CTA based on the draft assessment report provided by the RMS.
- Ethics Committee (EC): The CTA undergoes an ethical review by an ethics committee established in accordance with the national legislation of the respective Member State. Each Member State has its own designated ethics committee(s) responsible for this review, which may encompass aspects covered in both Part I and Part II of the CTA.
2. Key Considerations for Clinical Trial Applications
Under CTR 536/2014, a clinical trial application will be assessed in two parts:
- Part I assessment is led by the RMS and focuses on scientific and technical evaluation and evaluates aspects such as:
- The anticipated therapeutic and public health benefits.
- Compliance with the manufacturing and import requirements of the investigational medicinal product.
- Compliance with the investigational medicinal product's labelling requirements.
- The completeness and adequateness of the investigator's brochure.
- Part II Assessment is carried out by each CMS together with the respective national ECs and evaluates:
- Compliance with the requirements for informed consent.
- Compliance of the arrangements for rewarding or compensating trial subjects
- Compliance of subject recruitment process.
- The suitability of staff involved in the trial and the suitability of the trial sites.
- Compliance with requirements regarding compensation for any harm to subjects as a result of participating in the clinical trial.
3. Required Documents for CTA Submission
A Clinical Trial Application must typically include, but is not limited to:
- Cover Letter – specifying the EU trial number and any other information particular to the clinical trial
- Clinical Trial Protocol – Defines objectives, methodology, and statistical analysis of the trial.
- Investigator’s Brochure (IB) – Compilation of non-clinical and clinical data on the investigational medicinal product.
- Informed Consent Form: Contains information for the trial to be read and signed by participants to express willingness to participate in a trial.
- Summary of Product Characteristics (SmPC) – if the investigational medicinal product is already authorized; required for the evaluation of efficacy and safety.
- Investigational Medicinal Product (IMPD) – For regulatory information on the quality of the investigational medicinal product.
- EU CTA Form – The clinical trial application form is a web-based form to be completed on CTIS.
- Scientific Advice – A copy of any scientific advice letters, if available.
- Paediatric Investigation Plan (PIP) – If the clinical trial is part of an agreed PIP, a copy of EMA’s decision on the agreement on the PIP/waiver/deferral, and the opinion of the Paediatric Committee.
Why Clinical Trial Applications Matter
- Ensure Regulatory Compliance – Trials must be approved before they can start.
- Protect Participants – Ensures ethical, legal, and scientific oversight.
- Maintain Data Integrity – High-quality data ensures trial reliability.